Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ryplazim for Ligneous Conjunctivitis
NCT01554956Phase 3Completed
- Sponsor
- Kedrion Biopharma
- Start
- May 2013
- Primary completion
- Apr 2014
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of plasminogen, human in ligneous conjunctivitis, sponsored by Kedrion Biopharma. Primary endpoint: Percentage of Success to Prevent Pseudomembranes Relapse at 21 weeks. Started May 2013; status: completed.
02
Drugs
plasminogen, human
03
Conditions
ligneous conjunctivitis
Beyond the preview
Go deeper on NCT01554956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01554956.